Qiagen (QGEN) Q4 Earnings Lag Estimates

Company Performance - Qiagen reported quarterly earnings of $0.61 per share, missing the Zacks Consensus Estimate of$0.62 per share, but showing an increase from $0.57 per share a year ago, resulting in an earnings surprise of -1.61$521.2 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.09% and increasing from $509.16 million year-over-year [2] - Over the last four quarters, Qiagen has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Outlook - Qiagen shares have underperformed the market, losing about 5.3$0.52 on revenues of $479.38 million, and for the current fiscal year, it is$2.34 on revenues of $2.08 billion [7] - The estimate revisions trend for Qiagen is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Qiagen belongs, is currently in the top 30% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]